Pfizer Inc. (NYSE:PFE – Get Free Report) fell 1.5% during mid-day trading on Wednesday. The company traded as low as $28.00 and last traded at $28.0560. Approximately 37,233,295 shares traded hands during trading, a decline of 6% from the average session volume of 39,704,832 shares. The stock had previously closed at $28.47.
Pfizer News Summary
Investors following PFE have been watching these news items:
- Positive Sentiment: Pfizer secured exclusive rights outside Greater China to Starna Therapeutics’ three investigational in vivo CAR-T programs for autoimmune diseases. The agreement includes a $330 million upfront payment and up to $2.3 billion in potential milestones, adding a novel approach to Pfizer’s pipeline. Because the programs are preclinical, any commercial payoff is likely years away and uncertain. Article: Pfizer Secures Exclusive Rights To In Vivo CAR T Autoimmune Programs
- Positive Sentiment: A recent analysis said Pfizer’s launched and acquired products grew 32% in the third quarter, suggesting newer medicines are gaining traction and could help offset pressure on older products and COVID-related revenue. Article: Pfizer's Launched and Acquired Drugs Grew 32% in Q3
- Neutral Sentiment: Pfizer also reported updates to clinical studies, including an RSV booster study in older adults and a Phase 3 study of berobenatide. The entries provide no trial results, so they offer limited evidence of near-term commercial impact. Article: Pfizer Advances RSV Booster Study in Older Adults
Wall Street Analyst Weigh In
Several research firms have commented on PFE. Argus set a $40.00 price objective on Pfizer in a research note on Wednesday, November 4th. Scotiabank lifted their target price on Pfizer from $33.00 to $35.00 and gave the company a “sector outperform” rating in a research note on Wednesday, November 4th. FBN Securities set a $34.00 target price on Pfizer in a report on Friday, November 6th. JPMorgan Chase & Co. upped their price target on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research note on Friday, October 9th. Finally, Citigroup increased their price target on Pfizer from $27.00 to $30.00 and gave the stock a “neutral” rating in a report on Wednesday, November 4th. Six research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Pfizer presently has an average rating of “Hold” and a consensus price target of $30.32.
Read Our Latest Stock Report on Pfizer
Pfizer Trading Down 0.5%
The stock has a market capitalization of $156.25 billion, a PE ratio of 39.16, a PEG ratio of 1.84 and a beta of 0.31. The business’s 50-day moving average is $28.82 and its two-hundred day moving average is $27.03. The company has a current ratio of 1.42, a quick ratio of 1.10 and a debt-to-equity ratio of 0.67.
Pfizer (NYSE:PFE – Get Free Report) last released its quarterly earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.13. Pfizer had a net margin of 6.34% and a return on equity of 19.88%. The firm had revenue of $16.58 billion for the quarter, compared to the consensus estimate of $15.85 billion. During the same quarter in the previous year, the firm posted $0.87 EPS. The firm’s quarterly revenue was down .4% on a year-over-year basis. On average, analysts predict that Pfizer Inc. will post 3.04 earnings per share for the current year.
Pfizer Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Monday, December 7th. Investors of record on Friday, November 6th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.3%. The ex-dividend date is Friday, November 6th. Pfizer’s payout ratio is presently 245.71%.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of PFE. Stonebrook Private Inc. raised its holdings in shares of Pfizer by 114.8% during the 3rd quarter. Stonebrook Private Inc. now owns 23,866 shares of the biopharmaceutical company’s stock valued at $681,000 after purchasing an additional 12,757 shares in the last quarter. American Century Companies Inc. increased its position in Pfizer by 3.3% during the third quarter. American Century Companies Inc. now owns 1,272,906 shares of the biopharmaceutical company’s stock worth $36,303,000 after buying an additional 40,089 shares during the last quarter. Innovative Asset Advisors Group LLC raised its holdings in Pfizer by 1.5% during the third quarter. Innovative Asset Advisors Group LLC now owns 47,179 shares of the biopharmaceutical company’s stock valued at $1,346,000 after buying an additional 714 shares in the last quarter. Defiance ETFs LLC raised its holdings in Pfizer by 13.9% during the third quarter. Defiance ETFs LLC now owns 27,340 shares of the biopharmaceutical company’s stock valued at $780,000 after buying an additional 3,346 shares in the last quarter. Finally, Tradewinds LLC. lifted its position in shares of Pfizer by 31.8% in the third quarter. Tradewinds LLC. now owns 13,634 shares of the biopharmaceutical company’s stock worth $389,000 after buying an additional 3,288 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.
Pfizer Company Profile
Pfizer Inc. is a global biopharmaceutical company that researches, develops, manufactures and commercializes prescription medicines and vaccines. Its work spans areas including oncology, vaccines, internal medicine, inflammation and immunology, rare diseases, and infectious diseases. The company’s products include the Prevnar family of vaccines and medicines such as Eliquis, which it commercializes with Bristol Myers Squibb, and Paxlovid. Pfizer also developed the Comirnaty COVID-19 vaccine with BioNTech.
Recommended Stories
- Five stocks we like better than Pfizer
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
